Cargando…

Alopecia in Multiple Sclerosis Patients Treated with Disease Modifying Therapies

BACKGROUND: There is currently limited literature addressing the reporting of alopecia in multiple sclerosis (MS) patients treated with disease-modifying therapies (DMTs). Anecdotal reports of hair thinning from patients on various DMTs prompted further investigation of a large database. OBJECTIVE:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Porwal, Mokshal H., Salter, Amber, Patel, Dhruvkumar, Obeidat, Ahmed Z.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234852/ https://www.ncbi.nlm.nih.gov/pubmed/35769950 http://dx.doi.org/10.1177/11795735221109674

Ejemplares similares

Author response to comment on: Alopecia in multiple sclerosis patients treated with disease modifying therapies
por: Porwal, Mokshal H., et al.
Publicado: (2022)

Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice
por: Longbrake, Erin E, et al.
Publicado: (2016)

Disease-modifying therapy prescription patterns in people with multiple sclerosis by age
por: Zhang, Yinan, et al.
Publicado: (2021)

Testosterone-Mediated Aggression in Angelman Syndrome Treated With Leuprolide and Orchiectomy
por: Anderson, Danyon J, et al.
Publicado: (2022)

Clival intraosseous myxoma treated with an endoscopic endonasal approach: illustrative case
por: Porwal, Mokshal H., et al.
Publicado: (2023)

Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials
por: Zhang, Yinan, et al.
Publicado: (2020)

Disease Modifying Therapy in Multiple Sclerosis
por: Williams, U. E., et al.
Publicado: (2014)

Multiple Sclerosis, Disease-Modifying Therapies, and Infections
por: Langer-Gould, Annette M., et al.
Publicado: (2023)

Deep brain stimulation for refractory obsessive-compulsive disorder: A review and analysis of the FDA MAUDE database
por: Porwal, Mokshal H., et al.
Publicado: (2022)

A Targeted Literature Search and Phenomenological Review of Perspectives of People with Multiple Sclerosis and Healthcare Professionals of the Immunology of Disease-Modifying Therapies
por: Burtchell, Jeri, et al.
Publicado: (2022)

Clinical trials in multiple sclerosis: milestones
por: Zhang, Yinan, et al.
Publicado: (2018)

Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis
por: Simpson-Yap, Steve, et al.
Publicado: (2021)

Disease Modifying Agents for Multiple Sclerosis
por: Hilas, Olga, et al.
Publicado: (2010)

Oral Disease-Modifying Therapies for Multiple Sclerosis
por: Kim, Woojun, et al.
Publicado: (2015)

Editorial: Disease modifying therapies in multiple sclerosis
por: Bonavita, Simona, et al.
Publicado: (2022)

Adherence to Disease-Modifying Therapies for Multiple Sclerosis
por: Higuera, Lucas, et al.
Publicado: (2016)

Era of COVID-19 in Multiple Sclerosis Care
por: Krett, Jonathan D., et al.
Publicado: (2023)

Adherence to disease-modifying therapies in patients with multiple sclerosis
por: Kołtuniuk, Aleksandra, et al.
Publicado: (2018)

Evolution of clinical trials in multiple sclerosis
por: Zhang, Yinan, et al.
Publicado: (2019)

Three doses of COVID-19 vaccines in multiple sclerosis patients treated with disease-modifying therapies
por: Baba, Cavid, et al.
Publicado: (2022)

A survey of risk tolerance to multiple sclerosis therapies
por: Fox, Robert J., et al.
Publicado: (2019)

WITHDRAWN: Incidence and mortality of COVID-19 in Iranian multiple sclerosis patients treated with disease-modifying therapies
por: Etemadifar, M., et al.
Publicado: (2020)

Disease-Modifying Therapy in Multiple Sclerosis: Evaluation of Patients Satisfaction in Iranian Multiple Sclerosis Population
por: Molazadeh, Negar, et al.
Publicado: (2023)

Atypical Presentation of Acute Mitral Regurgitation Secondary to Papillary Muscle Rupture
por: Porwal, Kushal H, et al.
Publicado: (2022)

Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
por: Schweitzer, F., et al.
Publicado: (2020)

Attitudes toward coronavirus disease 2019 vaccination in people with multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2022)

New oral disease-modifying therapies for multiple sclerosis
por: Bagert, Bridget A, et al.
Publicado: (2009)

Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: González-Andrade, Fabricio, et al.
Publicado: (2010)

Disease-modifying therapies in multiple sclerosis in Latin America
por: Skromne-Eisenberg, Eli, et al.
Publicado: (2017)

Safety of Newer Disease Modifying Therapies in Multiple Sclerosis
por: Jalkh, Georges, et al.
Publicado: (2020)

Changes in John Cunningham Virus Index in Multiple Sclerosis Patients Treated with Different Disease-Modifying Therapies
por: Sgarlata, Eleonora, et al.
Publicado: (2022)

COVID-19 vaccines and multiple sclerosis disease-modifying therapies
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Opinion: The role of the registered dietitian nutritionist in multiple sclerosis care in the United States
por: Titcomb, Tyler J., et al.
Publicado: (2023)

Analysis of reported adverse events of pipeline stents for intracranial aneurysms using the FDA MAUDE database
por: Porwal, Mokshal H., et al.
Publicado: (2023)

Uptake and Attitudes About Immunizations in People With Multiple Sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2021)

MedCDI: A technology-based documentation and quality improvement initiative in neurosurgery
por: Porwal, Mokshal H., et al.
Publicado: (2022)

Visual oscillation effects on dynamic balance control in people with multiple sclerosis
por: Riem, Lara, et al.
Publicado: (2022)

Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis
por: Bross, Madeline, et al.
Publicado: (2020)

Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis
por: Zanga, Gisela, et al.
Publicado: (2021)

Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies
por: Simone, Isabella Laura, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u1634akr20hes90n36outgb106